SELLAS Life Science announced that the pre-specified threshold of 60 events has been reached in its ongoing Phase 3 REGAL clinical trial of galinpepimut-S, GPS, in acute myeloid leukemia, AML, triggering the interim analysis to be conducted by the Independent Data Monitoring Committee, IDMC.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SLS:
- Sellas Life Sciences reports OS, ORR data from Phase 2 trial of SLS009
- Sellas Life Sciences announces data from preclinical studies of SLS009
- Largest borrow rate increases among liquid names
- Sellas Life Sciences reports Q3 EPS (10c), consensus (13c)
- SLS Upcoming Earnings Report: What to Expect?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
